House objects to Pfizer's Lipitor pitchman

I'm not a practicing doctor, nor do I play one on TV--but I did go to med school! Promise! That's what we imagine Dr. Robert Jarvik (photo) saying to Congress when questioned about his role as cholesterol drug pitchman for Pfizer. House Democrats are investigating whether consumers are misled by Jarvik's endorsement; though he invented the artificial heart, he has never practiced medicine.

So, Jarvik's now poster boy for a probe of DTC advertising. He "appears to be giving medical advice," but he's not qualified to do so, says Rep. John Dingell, chairman of a House subcommittee. But Pfizer maintains that Jarvik is well aware that patients need to take steps to protect their hearts--namely from high cholesterol, we assume--so they never need the kind of replacement he pioneered. What, we wonder, would Dingell have made of Marcus Welby, M.D.'s, pitch for Geritol?

- see the release from the House Committee on Energy and Commerce
- read the report from the International Herald Tribune

Related Articles:
Study: DTC ad spending on the rise. Report
10 reforms for drug advertising. Report
FDA to study TV drug ad imagery. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.